A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Completed · Phase 4 · NCT03886220
Conditions: Uterine Fibroids
At a glance
- Research payments reported, 2025
- $3,500
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 82
About the trial
- Sponsor
- AbbVie
- Tested
- Elagolix (drug), Placebo (drug)
- Dates
- Started 2019-04-12; completion 2021-04-28
- Results posted
- Yes
The main objective of this study is to assess safety and efficacy of elagolix compared to placebo in reducing heavy menstrual bleeding (HMB) associated with uterine fibroids in premenopausal women. The primary hypothesis is that elagolix, compared to placebo, reduces HMB associated with uterine fibroids in premenopausal women.
From ClinicalTrials.gov, last updated 2022-03-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3,500 in research payments for this study in 2025 (1 payments).
Products named: Orilissa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gcp Clinical Research LLC $3,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.